“Europe’s pharmaceutical industry, struggling with huge research costs and unfriendly regulation, has been limping along for more than a decade. To help the ailing sector, the European Union (EU) in 2007 launched the multibillion-euro Innovative Medicines Initiative (IMI) to bring public and private researchers together and speed up drug development …” (more)
[Natasha Gilbert, Nature, 13 July]